

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) An isolated transgenic somatic or embryonic stem cell having a mutant endogenous p27^{Kip1} gene lacking a Cdk2 phosphorylation site, wherein the mutant p27^{Kip1} gene encodes a mutant p27^{Kip1} polypeptide having a longer half-life in S phase than wildtype p27^{Kip1} polypeptide, and wherein the mutation results in a loss of endogenous wild-type p27^{Kip1}.

2. (Original) The transgenic cell of claim 1, wherein the mutant p27^{Kip1} polypeptide inhibits Cdk2 *in vitro* kinase activity.

3. (Original) The transgenic cell of claim 1, wherein the mutant p27^{Kip1} polypeptide is p27^{T187A}.

4. - 5. (Cancelled)

6. (Currently amended) The transgenic murine cell of claim [[4]] 39, wherein the cell is a somatic cell, a primordial germ cell, an oocyte, egg, spermatocyte, sperm cell, fertilized egg, zygote, or embryonic stem cell.

7. (Currently amended) The transgenic murine cell of claim 6, wherein the murine cell is an oocyte, fertilized egg, sperm cell or spermatocyte.

8. - 37 (Cancelled)

38. (New) A transgenic murine cell having a mutant endogenous p27^{Kip1} gene lacking a Cdk2 phosphorylation site, wherein the mutant p27^{Kip1} gene encodes a mutant p27^{Kip1} polypeptide having a longer half-life in S phase than wild-type p27^{Kip1} polypeptide.